Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Single-arm Clinical Study of Orelabrutinib Plus Rituximab for Second-line Treatment of Relapsed/Refractory Marginal Zone Lymphoma

NCT06134284 is registered in ClinicalTrials.gov with Lixia Sheng as lead sponsor.

NCT NCT06134284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06134284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Single-arm Clinical Study of Orelabrutinib Plus Rituximab for Second-line Treatment of Relapsed/Refractory Marginal Zone Lymphoma
Lead sponsor
Lixia Sheng
Phase
Phase 4
Overall status
Recruiting
Start date
January 2, 2023
Completion date
December 31, 2029
Enrollment
39 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

or regimen for relapsed/refractory marginal zone lymphoma